Chutes and ladders in hepatitis C nucleoside drug development - Test2 - elhamkhani - TriplyDB

Chutes and ladders in hepatitis C nucleoside drug development

Chutes and ladders in hepatitis C nucleoside drug development

http://www.wikidata.org/entity/Q26998630

about

Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Synthesis and Evaluation of 2'-Deoxy-2'-Spirodiflurocyclopropyl Nucleoside Analogs.Design, synthesis and antiviral evaluation of 2'-C-methyl branched guanosine pronucleotides: the discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor.Norovirus infection in primary immune deficiency.Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase.Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys.Synthesis of 1'-C-cyano pyrimidine nucleosides and characterization as HCV polymerase inhibitors.In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Polymerase activity and mechanisms of action of nucleotide analogs.Revisiting the linkage between ethnomedical use and development of new medicines: A novel plant collection strategy towards the discovery of anticancer agents.Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection.Recent advances in synthetic approaches for medicinal chemistry of C-nucleosides.

P2860

Q26700073-44F308FC-E310-481E-BD20-03419228CCE2 Q29994527-DDBDE501-D2D0-4E32-B070-0848F7924982 Q34481846-43CAA471-05E2-4824-B203-5BACBE55384D Q35491398-8E67B5E1-F23F-407B-B6DF-53D453EADF01 Q38515906-CFFDD6D4-EBE0-4B84-A311-56A3883B6624 Q38750398-96E99449-E7CE-4310-B59E-66A1E5B988A6 Q38958064-33CCB4E5-91A2-4D98-843F-9D4C6B615AB6 Q39167685-A04FECED-28D6-4E0B-A1B4-FE5575FA72A7 Q39742470-19F30A57-1EB9-4FB9-9B05-FB21087123B1 Q40180055-33C9B852-7173-4E69-AE08-9A500EB4322E Q41126428-DF395A58-0FAD-4093-B161-B9BF15D53D65 Q41329890-7F6A97FB-12C9-4295-AE3F-17B456EEDFFB Q41585354-928AC551-47F2-45A4-BBFF-41E421992A80 Q41783595-3CC562F5-FF42-4844-9711-52BD6BEDA201 Q41919256-DFDA84B8-5979-43D1-B2C9-9092C8EB3F44 Q46258832-1C54AF58-B12F-4F63-A752-F95AEE4926CD Q47601762-6E8E3BC9-26F6-4F11-990A-E0EE6D72987F Q49797854-0EFB0097-FF49-4EF6-9EEF-B60074FF54BD Q54985694-51D01D4E-DB0E-4A00-82AB-942BAC2B5C7C

P2860

Chutes and ladders in hepatitis C nucleoside drug development

http://www.wikidata.org/entity/Q26998630

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Chutes and ladders in hepatitis C nucleoside drug development

@ast

Chutes and ladders in hepatitis C nucleoside drug development

@en

Chutes and ladders in hepatitis C nucleoside drug development

@nl

type

label

Chutes and ladders in hepatitis C nucleoside drug development

@ast

Chutes and ladders in hepatitis C nucleoside drug development

@en

Chutes and ladders in hepatitis C nucleoside drug development

@nl

prefLabel

Chutes and ladders in hepatitis C nucleoside drug development

@ast

Chutes and ladders in hepatitis C nucleoside drug development

@en

Chutes and ladders in hepatitis C nucleoside drug development

@nl

P1433

Q26998630-08D61A0C-903B-442D-85D9-7E08CFF204BE

P1476

Q26998630-F339A6D2-F03D-4E97-804B-037F7EC199E6

P2093

Q26998630-037B7E4B-67EF-4204-AD89-3AD804E157EA

Q26998630-49926661-491C-46EF-9F7B-83ECCEF3A47D

Q26998630-4C571D3A-389D-41D1-BA1A-349554034151

Q26998630-616DB1C2-CE4B-44F5-8CDD-76930C31516A

Q26998630-61BC7860-3CA6-4B7D-B6B2-F4174E47682C

Q26998630-644C0575-9611-45CF-8F07-465354A7EC0F

Q26998630-7260D457-FCC0-4F05-B229-C9D57923FBFD

Q26998630-7E7DE416-33B0-422D-A616-E0F88BDECB71

Q26998630-80B1AFEC-902C-4863-B07D-E6C32D1B9EB6

Q26998630-88B70AA1-9C42-47B4-8D9A-51971566E09A

P2860

Q26998630-02C6AB25-16B0-4E3E-BC99-AD344A7703C2

Q26998630-085D40AC-ED80-4F6B-8BDA-D9CEB43C17C1

Q26998630-092C7E1C-1C83-436B-BCFD-069DE4C67A70

Q26998630-0B5DCB7A-35E8-4DB6-8B60-B1F6687DF93B

Q26998630-0FC72C52-21C8-49FA-AEFB-A8FF2A055864

Q26998630-1089DD5B-BD5A-4F2D-A873-A99116CDB854

Q26998630-117ADC25-61D0-4B44-A8C2-AB89D8AFB6E7

Q26998630-122CDFE1-0BDA-4B12-85CC-31F8D9F04B46

Q26998630-14ED1B30-4B88-4130-8CFE-9F82F597B04B

Q26998630-18F87880-C860-40A8-8F8E-7CB52A61BDB5

P304

Q26998630-FF361885-C0DB-47BF-8A6C-DB6103BEA491

P31

Q26998630-36A5D5BB-64A6-4D60-BBAE-8847EAD0E2FB

P356

Q26998630-63664E9E-7A9C-4541-B2C6-03C32A673660

P407

Q26998630-A35F767B-8C90-4BA3-88F1-FEE81D509DBF

P478

Q26998630-11DCB4B0-9B0E-472E-AE64-2394B909A37B

P50

Q26998630-56BAF9AB-72AA-4D57-998F-1BF6FDAEB9C6

Q26998630-925056B1-4D64-46A7-8352-5545485DCB5B

P577

Q26998630-DBAF3EA8-E401-4569-966B-041DB0ECDBD3

P698

Q26998630-3E6902C7-A577-47BC-8954-669D1B187FAA

P932

Q26998630-A2E16CE2-D83E-4F63-A1F8-0BB86FD9478A

P356

J.ANTIVIRAL.2013.11.008

P1433

Antiviral Research

P1476

Chutes and ladders in hepatitis C nucleoside drug development

@en

P2093

Chengwei Li

http://www.w3.org/2001/XMLSchema#string

Ethel C. Garnier-Amblard

http://www.w3.org/2001/XMLSchema#string

Franck Amblard

http://www.w3.org/2001/XMLSchema#string

Hao Li

http://www.w3.org/2001/XMLSchema#string

Hongwang Zhang

http://www.w3.org/2001/XMLSchema#string

Jadd R. Shelton

http://www.w3.org/2001/XMLSchema#string

Jong Hyun Cho

http://www.w3.org/2001/XMLSchema#string

Judy Mathew

http://www.w3.org/2001/XMLSchema#string

Lavanya Bondada

http://www.w3.org/2001/XMLSchema#string

Longhu Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatitis C: a review for primary care physicians

Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977

Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.

Mechanism of Activation of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase

The Mechanism of Action of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system

Best strategies for global HCV eradication.

P304

119-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ANTIVIRAL.2013.11.008

http://www.w3.org/2001/XMLSchema#string

P407

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Sebastien R.L. Boucle

Raymond F. Schinazi

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24275341

http://www.w3.org/2001/XMLSchema#string

P932

3910353

http://www.w3.org/2001/XMLSchema#string